Show simple item record

dc.contributor.authorRangachari, Deepa
dc.contributor.authorYamaguchi, Norihiro
dc.contributor.authorVanderlaan, Paul A
dc.contributor.authorFolch, Erik E
dc.contributor.authorMahadevan, Anand
dc.contributor.authorFloyd, Scott R.
dc.contributor.authorUhlmann, Erik J
dc.contributor.authorWong, Eric S.
dc.contributor.authorDahlberg, Suzanne Eleanor
dc.contributor.authorHuberman, Mark S.
dc.contributor.authorCosta, Daniel Botelho
dc.date.accessioned2018-05-18T20:25:45Z
dc.date.issued2015
dc.identifierQuick submit: 2017-07-13T12:40:50-0400
dc.identifier.citationRangachari, Deepa, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan, Scott R. Floyd, Erik J. Uhlmann, et al. 2015. “Brain Metastases in Patients with EGFR -Mutated or ALK -Rearranged Non-Small-Cell Lung Cancers.” Lung Cancer 88 (1) (April): 108–111. doi:10.1016/j.lungcan.2015.01.020.en_US
dc.identifier.issn0169-5002en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:37034617
dc.description.abstractIntroduction—Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC). However, the baseline incidence and evolution of BM over time in oncogene-driven NSCLCs are seldom reported. In this study, we evaluated the frequency of BM in patients with epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged NSCLC. Methods—The presence of BM, clinicopathologic data, and tumor genotype were retrospectively compiled and analyzed from a cohort of 381 patients. Results—We identified 86 EGFR-mutated (90.7% with metastatic disease; 85.9% received an EGFR inhibitor) and 23 ALK-rearranged (91.3% with metastatic disease; 85.7% received an ALK inhibitor) NSCLCs. BM were present in 24.4% of EGFR-mutated and 23.8% of ALK-rearranged NSCLCs at the time of diagnosis of advanced disease. This study did not demonstrate a difference in the cumulative incidence of BM over time between the two cohorts (EGFR/ALK cohort competing risk regression [CRR] coefficient of 0.78 [95% CI 0.44–1.39], p=0.41). In still living patients with advanced EGFR-mutated NSCLC, 34.2% had BM at 1 year, 38.4% at 2 years, 46.7% at 3 years, 48.7% at 4 years, and 52.9% at 5 years. In still living patients with advanced ALKrearranged NSCLC, 23.8% had BM at 1 year, 45.5% at 2 years, and 58.4% at 3 years. Conclusions—BM are frequent in advanced EGFR-mutated or ALK-rearranged NSCLCs, with an estimated >45% of patients with CNS involvement by three years of survival with the use of targeted therapies. These data point toward the CNS as an important unmet clinical need in the evolving schema for personalized care in NSCLC.en_US
dc.language.isoen_USen_US
dc.publisherElsevier BVen_US
dc.relation.isversionof10.1016/j.lungcan.2015.01.020en_US
dash.licenseOAP
dc.titleBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersen_US
dc.typeJournal Articleen_US
dc.date.updated2017-07-13T16:40:56Z
dc.description.versionAccepted Manuscripten_US
dc.relation.journalLung Canceren_US
dash.depositing.authorVanderlaan, Paul A
dc.date.available2015
dc.date.available2018-05-18T20:25:45Z
dc.identifier.doi10.1016/j.lungcan.2015.01.020*
workflow.legacycommentscat.completeen_US
dash.authorsorderedfalse
dash.contributor.affiliatedUhlmann, Erik
dash.contributor.affiliatedFolch, Erik
dash.contributor.affiliatedRangachari, Deepa
dash.contributor.affiliatedCosta, Daniel
dash.contributor.affiliatedSzwarc, Suzanne
dash.contributor.affiliatedWong, Eric
dash.contributor.affiliatedVanderlaan, Paul


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record